Sandimmun Neoral 50 mg Nórsko - nórčina - Statens legemiddelverk

sandimmun neoral 50 mg

novartis norge (2) - ciklosporin - kapsel, myk - 50 mg

Sandimmun Neoral 100 mg Nórsko - nórčina - Statens legemiddelverk

sandimmun neoral 100 mg

novartis norge (2) - ciklosporin - kapsel, myk - 100 mg

Tacni 1 mg Nórsko - nórčina - Statens legemiddelverk

tacni 1 mg

teva sweden ab - takrolimus - kapsel, hard - 1 mg

Tacni 0.5 mg Nórsko - nórčina - Statens legemiddelverk

tacni 0.5 mg

teva sweden ab - takrolimus - kapsel, hard - 0.5 mg

Kymriah Európska únia - nórčina - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Poteligeo Európska únia - nórčina - EMA (European Medicines Agency)

poteligeo

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastiske midler - poteligeo er indisert for behandling av voksne pasienter med mycosis fungoides (mf) eller sézary syndrom (ss) som har mottatt minst én tidligere systemisk terapi.

Libtayo Európska únia - nórčina - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karsinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Hypotron 5 mg Nórsko - nórčina - Statens legemiddelverk

hypotron 5 mg

brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 5 mg

Hypotron 2.5 mg Nórsko - nórčina - Statens legemiddelverk

hypotron 2.5 mg

brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 2.5 mg

Voriconazole Fresenius Kabi 200 mg Nórsko - nórčina - Statens legemiddelverk

voriconazole fresenius kabi 200 mg

fresenius kabi norge as - vorikonazol - pulver til infusjonsvæske, oppløsning - 200 mg